Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 2, 2012, Pages 488-498

  Panarsky, Rony ^a   Luques, Lisandro ^a   Weinstock, Marta ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Aging rats; Cytokines; Lipopolysaccharide; Microglia; Mitogen activated protein kinase; Nitric oxide

Indexed keywords

6 (N ETHYL, N METHYL CARBAMYLOXY) 1 AMINOINDAN; 6 (N METHYL CARBAMYLOXY) N PROPARGYL 1 AMINOINDAN; CHOLINESTERASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; LADOSTIGIL; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; (N PROPARGYL (3R) AMINOINDAN 5 YL) ETHYL METHYL CARBAMATE; (N-PROPARGYL-(3R) AMINOINDAN-5-YL)-ETHYL METHYL CARBAMATE; ANTIINFLAMMATORY AGENT; INDAN DERIVATIVE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TRANSLOCATION; MICROGLIA; NONHUMAN; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPATIAL MEMORY; AGING; ANIMAL; BRAIN; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; MALE; MAZE TEST; MEMORY; METABOLISM; OXIDATIVE STRESS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WISTAR RAT;

AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; BRAIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; INDANS; MALE; MAZE LEARNING; MEMORY; MICROGLIA; OXIDATIVE STRESS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84866504849     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-012-9358-z     Document Type: Article

References (46)

1. Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591. doi:10.1146/annurev.immunol.15.1.563 (Pubitemid 27169292)
2. Bar-Am O, Weinreb O, Amit T, Youdim MB (2009) The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 37(2):135-145. doi:10.1007/s12031-008-9139-6
3. Bhat NR, Zhang P, Lee JC, Hogan EL (1998) Extracellular signalregulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 18(5):1633-1641 (Pubitemid 28103071)
4. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW (2003) Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23(9):3807-3819 (Pubitemid 36958487)
5. Boje KM, Arora PK (1992) Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 587(2):250-256
6. Brown MA, Jones WK (2004) NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 9:1201-1217 (Pubitemid 39060836)
7. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R (2007) Elevated levels of 3- nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 1148:243-248. doi:10.1016/j.brainres.2007.02.084 (Pubitemid 46602178)
8. Colby CL, Goldberg ME (1999) Space and attention in parietal cortex. Annu Rev Neurosci 22:319-349. doi:10.1146/annurev.neuro.22.1.319 (Pubitemid 29144891)
9. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415-1421 (Pubitemid 24217131)
10. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E (2003) Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 17(2):117-126 (Pubitemid 36736847)
11. Frost RA, Nystrom GJ, Lang CH (2004) Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C(2)C(12) myoblasts via Toll-like receptor-4 and c-Jun NH (2)-terminal kinase pathways. Am J Physiol Cell Physiol 287(6): C1605-C1615. doi:10.1152/ajpcell.00010.200400010.2004 (Pubitemid 39507678)
12. GallagherM, Burwell R, Burchinal M(1993) Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107(4):618-626 (Pubitemid 23259627)
13. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13(2):85-94 (Pubitemid 32222977)
14. Hwang J, Hwang H, Lee HW, Suk K (2010) Microglia signaling as a target of donepezil. Neuropharmacology 58(7):1122-1129. doi:10.1016/j.neuropharm.2010.02. 003
15. Kiss (2007) Pharmacokinetic study and metabolic profiling in rats following a single oral administration of 14C-ladostigil tartrate. Pharmaceutical Works, Hungary Final Report No SB-2006-004
16. Koistinaho M, Koistinaho J (2002) Role of p38 and p44/42 mitogenactivated protein kinases in microglia. Glia 40(2):175-183. doi:10.1002/glia.10151 (Pubitemid 35337375)
17. Li AJ, Katafuchi T, Oda S, Hori T, Oomura Y (1997) Interleukin-6 inhibits long-term potentiation in rat hippocampal slices. Brain Res 748(1-2):30-38 (Pubitemid 27094880)
18. Li C, Zhao R, Gao K, Wei Z, Yin MY, Lau LT, Chui D, Hoi Yu AC (2011) Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res 8(1):67-80
19. Luques L, Shoham S, Weinstock M (2007) Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil. Exp Neurol 206(2):209-219. doi:10.1016/j.expneurol.2007.04.007 (Pubitemid 47103175)
20. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO (2009) The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 1153:240-246. doi:10.1111/j.1749-6632.2008.03972.x
21. Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R, Mecocci P (2009) Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 8(4):285-305. doi:10.1016/j.arr.2009.04.002
22. Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]- ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341 (3):233-236 (Pubitemid 36403771)
23. Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119(4):252-265. doi:10.1111/j.1600-0447.2008.01326.x
24. Moynagh PN (2005) The NF-kappaB pathway. J Cell Sci 118(Pt 20):4589-4592. doi:10.1242/jcs.02579 (Pubitemid 41646369)
25. Murray CA, Lynch MA (1998) Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci 18(8):2974-2981 (Pubitemid 28163227)
26. Nitz D (2009) Parietal cortex, navigation, and the construction of arbitrary reference frames for spatial information. Neurobiol Learn Mem 91(2):179-185. doi:10.1016/j.nlm.2008.08.007
27. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ (2009) Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72(1):56-62. doi:10.1212/01.wnl.0000338622.27876.0d
28. Palmer K, Berger AK, Monastero R,Winblad B, Backman L, Fratiglioni L (2007) Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 68(19):1596-1602. doi:10.1212/01.wnl.0000260968.92345.3f (Pubitemid 46717984)
29. Park LC, Zhang H, Sheu KF, Calingasan NY, Kristal BS, Lindsay JG, Gibson GE (1999) Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia. J Neurochem 72(5):1948-1958 (Pubitemid 29185998)
30. Persson CM,WallinAK, Levander S, Minthon L (2009) Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. BMC Neurol 9:7. doi:10.1186/1471-2377-9-7
31. Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4(11):e338. doi:10.1371/journal.pmed.0040338 (Pubitemid 350220534)
32. Reichert F, Rotshenker S (2003) Complement-receptor-3 and scavenger-receptor-AI/II mediated myelin phagocytosis in microglia and macrophages. Neurobiol Dis 12(1):65-72
33. Rost KL (2003) A Phase-I, randomized, double-blind, placebo controlled, ascending single dose study to assess the safety, tolerability and pharmacokinetics of TV 3326 in healthy male volunteers. Parexel, Berlin, Germany Final Report Study No TV-3326/101
34. Roy A, Jana A, Yatish K, Freidt MB, Fung YK, Martinson JA, Pahan K (2008) Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: implications for neurodegenerative diseases. Free Radic Biol Med 45(5):686-699. doi:10.1016/j.freeradbiomed.2008.05.026
35. Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21(1):172-188. doi:10.1021/tx700210j (Pubitemid 351219718)
36. Schneider LS, Insel PS, Weiner MW (2011) Alzheimer's disease neuroimaging initiative. Treatment with cholinesterase inhibitors and memantine of patients in the alzheimer's disease neuroimaging initiative. Arch Neurol 68(1):58-66
37. Smith MA, Nunomura A, Lee HG, Zhu X, Moreira PI, Avila J, Perry G (2005) Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging 26(5):579-580. doi:10.1016/j.neurobiolaging.2004.09.021 (Pubitemid 40228747)
38. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Finberg J, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB, Weinstock M (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45(24):5260-5279 (Pubitemid 35429165)
39. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 20(6):947-956. doi:10.1159/000110455 (Pubitemid 350059737)
40. Wang Z, Ma W, Chabot JG, Quirion R (2010) Calcitonin gene-related peptide as a regulator of neuronal CaMKII-CREB, microglial p38-NFkappaB and astroglial ERK-Stat1/3 cascades mediating the development of tolerance to morphine-induced analgesia. Pain 151(1):194-205. doi:10.1016/j.pain.2010.07.006
41. Weinstock M (2005) Kinetic studies on the interaction of acetylcholinesterase with ladostigil and its major metabolites. Final Report to Teva No TV-3326/MWR/014
42. Weinstock M, Goren T, Youdim MBH (2000) Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 50:216-222
43. Weinstock M, Luques L, Poltyrev T, Bejar C, Shoham S (2011) Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol Aging 32(6):1069-1078. doi:10.1016/j.neurobiolaging.2009.06.004
44. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J (2004) Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21(7):453-478 (Pubitemid 38736890)
45. Youdim MB, Weinstock M (2001) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 21(6):555-573 (Pubitemid 34538855)
46. Yuan H, Wang WP, Feng N, Wang L, Wang XL (2011) Donepezil attenuated oxygen-glucose deprivation insult by blocking Kv2.1 potassium channels. Eur J Pharmacol 657(1-3):76-83. doi:10.1016/j.ejphar.2011.01.054